Disruption of FBXL5-mediated Cellular Iron Homeostasis Promotes Liver Carcinogenesis

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2019 Mar 17

PMID 30877170

Citations 27

Authors

Yoshiharu Muto

Toshiro Moroishi

Kazuya Ichihara

Masaaki Nishiyama

Hideyuki Shimizu

Hidetoshi Eguchi

Kyoji Moriya

Kazuhiko Koike

Koshi Mimori

Masaki Mori

Yuta Katayama

Keiichi I Nakayama

Affiliations

Soon will be listed here.

Abstract

Hepatic iron overload is a risk factor for progression of hepatocellular carcinoma (HCC), although the molecular mechanisms underlying this association have remained unclear. We now show that the iron-sensing ubiquitin ligase FBXL5 is a previously unrecognized oncosuppressor in liver carcinogenesis in mice. Hepatocellular iron overload elicited by FBXL5 ablation gave rise to oxidative stress, tissue damage, inflammation, and compensatory proliferation of hepatocytes and to consequent promotion of liver carcinogenesis induced by exposure to a chemical carcinogen. The tumor-promoting outcome of FBXL5 deficiency in the liver was also found to be effective in a model of virus-induced HCC. FBXL5-deficient mice thus constitute the first genetically engineered mouse model of liver carcinogenesis promoted by iron overload. In addition, dysregulation of FBXL5-mediated cellular iron homeostasis was found to be associated with poor prognosis in human HCC, suggesting that FBXL5 plays a key role in defense against hepatocarcinogenesis.

Citing Articles

Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target.

Chen H Liver Res. 2025; 6(4):203-213.

PMID: 39957910 PMC: 11791839. DOI: 10.1016/j.livres.2022.09.003.

Editorial: Community series in post-translational modifications of proteins in cancer immunity and immunotherapy, volume III.

Zhao X, Nihira N, Dai X, Liu Z Front Immunol. 2024; 15:1533926.

PMID: 39723216 PMC: 11668628. DOI: 10.3389/fimmu.2024.1533926.

Cis-Regulation of an mA Eraser by an Insertion Variant Associated with Survival of Patients With Non-Small Cell Lung Carcinoma.

Cheng L, Hu Q, Wang Y, Nie W, Lu H, Zhang B Adv Sci (Weinh). 2024; 12(5):e2407652.

PMID: 39680684 PMC: 11791940. DOI: 10.1002/advs.202407652.

Assessment of the Impact of Trace Essential Metals on Cancer Development.

Gorska A, Markiewicz-Gospodarek A, Trubalski M, Zerebiec M, Poleszak J, Markiewicz R Int J Mol Sci. 2024; 25(13).

PMID: 38999951 PMC: 11241304. DOI: 10.3390/ijms25136842.

Chen C, Chen Z, Zhou Z, Ye H, Xiong S, Hu W Front Immunol. 2024; 15:1424752.

PMID: 38919610 PMC: 11196398. DOI: 10.3389/fimmu.2024.1424752.

References

Zhang N, Liu J, Ding X, Aikhionbare F, Jin C, Yao X . FBXL5 interacts with p150Glued and regulates its ubiquitination. Biochem Biophys Res Commun. 2007; 359(1):34-9. DOI: 10.1016/j.bbrc.2007.05.068. View

Cheung K, Zhao J, Hao Y, Li X, Lowe A, Cheng A . CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth. Cancer. 2012; 119(6):1217-26. DOI: 10.1002/cncr.27865. View

Ngo H, Kim D, Cha Y, Na H, Surh Y . Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis. Cancer Res. 2017; 77(18):4797-4808. DOI: 10.1158/0008-5472.CAN-16-3538. View

Mohs A, Kuttkat N, Reissing J, Zimmermann H, Sonntag R, Proudfoot A . Functional role of CCL5/RANTES for HCC progression during chronic liver disease. J Hepatol. 2016; 66(4):743-753. DOI: 10.1016/j.jhep.2016.12.011. View

Girelli D, Pasino M, Goodnough J, Nemeth E, Guido M, Castagna A . Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009; 51(5):845-52. PMC: 2761995. DOI: 10.1016/j.jhep.2009.06.027. View

Coudray A, Battenhouse A, Bucher P, Iyer V . Detection and benchmarking of somatic mutations in cancer genomes using RNA-seq data. PeerJ. 2018; 6:e5362. PMC: 6074801. DOI: 10.7717/peerj.5362. View

Katayama Y, Nishiyama M, Shoji H, Ohkawa Y, Kawamura A, Sato T . CHD8 haploinsufficiency results in autistic-like phenotypes in mice. Nature. 2016; 537(7622):675-679. DOI: 10.1038/nature19357. View

Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I . ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2016; 13(1):91-98. PMC: 5610546. DOI: 10.1038/nchembio.2239. View

Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G . Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996; 110(4):1107-19. DOI: 10.1053/gast.1996.v110.pm8613000. View

10.

Britton L, Subramaniam V, Crawford D . Iron and non-alcoholic fatty liver disease. World J Gastroenterol. 2016; 22(36):8112-22. PMC: 5037080. DOI: 10.3748/wjg.v22.i36.8112. View

11.

Vinas-Castells R, Frias A, Robles-Lanuza E, Zhang K, Longmore G, Garcia de Herreros A . Nuclear ubiquitination by FBXL5 modulates Snail1 DNA binding and stability. Nucleic Acids Res. 2013; 42(2):1079-94. PMC: 3902928. DOI: 10.1093/nar/gkt935. View

12.

Moroishi T, Nishiyama M, Takeda Y, Iwai K, Nakayama K . The FBXL5-IRP2 axis is integral to control of iron metabolism in vivo. Cell Metab. 2011; 14(3):339-51. DOI: 10.1016/j.cmet.2011.07.011. View

13.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

14.

Martinelli A, Filho A, Franco R, Tavella M, N Z Ramalho L, Zucoloto S . Liver iron deposits in hepatitis B patients: association with severity of liver disease but not with hemochromatosis gene mutations. J Gastroenterol Hepatol. 2004; 19(9):1036-41. DOI: 10.1111/j.1440-1746.2004.03410.x. View

15.

Deugnier Y, Charalambous P, le Quilleuc D, Turlin B, Searle J, Brissot P . Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology. 1993; 18(6):1363-9. View

16.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

17.

Bacon B, Adams P, Kowdley K, Powell L, Tavill A . Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(1):328-43. PMC: 3149125. DOI: 10.1002/hep.24330. View

18.

Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad I . Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44(6):694-8. PMC: 3819251. DOI: 10.1038/ng.2256. View

19.

Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

20.

Sorrentino P, DAngelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R . Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol. 2008; 50(2):351-7. DOI: 10.1016/j.jhep.2008.09.011. View